REperfusion With Cooling in CerebraL Acute IscheMia II

NCT ID: NCT03804060

Last Updated: 2024-05-16

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 90 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-05-23
• Study Completion Date: 2024-05-01

Brief Summary

The primary objective of this study is to determine the feasibility and safety of achieving rapid hypothermia with the Proteus Intravascular Temperature Management (IVTM) system for patients experiencing acute ischemic stroke due to a large vessel occlusion.

Conditions

Ischemic Stroke

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Cooling + Recanalization

The subjects will be considered to be enrolled in the Test Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Test Arm of the trial to allow cooling with the Thermogard XP3 IVTM System before and after recanalization.

Group Type: EXPERIMENTAL

Thermogard XP3

Intervention Type: DEVICE

Cooling with the ZOLL® Circulation catheter and the ZOLL® Intravascular Temperature Management system to initiate and maintain hypothermia for 6 hours as an adjunct to endovascular Recanalization.

Recanalization only

The subjects will be considered to be enrolled in the Control Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Control Arm of the trial to allow recanalization only.

Group Type: ACTIVE_COMPARATOR

Recanalization only

Intervention Type: PROCEDURE

Standard of Care for recanalization

Interventions

Thermogard XP3

Cooling with the ZOLL® Circulation catheter and the ZOLL® Intravascular Temperature Management system to initiate and maintain hypothermia for 6 hours as an adjunct to endovascular Recanalization.

Intervention Type: DEVICE

Recanalization only

Standard of Care for recanalization

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

1. Age ≥18 and ≤85;

2. Signs and symptoms consistent with an acute ischemic stroke with anterior circulation large vessel occlusion (M1 MCA, carotid-terminus occlusion, Tandem occlusion allowed (Extracranial ICA+carotid T or M1 MCA)) as determined by CT imaging; (i.e., hyperdense sign on non-contrast CT or CT angiogram);

3. Ability to perform arterial puncture within 24 hours from symptom onset or LKN;

4. ASPECTS score of 6-10 on non-contrast CT of the brain if under 80 years; ASPECTS 9-10 if age 80-85;

5. For transfer patients with anticipated arterial puncture greater than 6 hours from symptom onset or LKN, qualifying imaging must be performed within 2 hours prior to enrolling hospital arrival; or with a newly obtained non-contrast CT scan if this time is exceeded

6. Candidate for endovascular thrombectomy therapy in accordance with best practices per AHA standard stroke guidelines meeting all labeling requirements for EVT in the trial;

7. No contraindications to general anesthesia, conscious sedation or allergies to any components associated with the anticipated diagnostic or treatment procedures that cannot be treated;

8. A pre-stroke modified Rankin Score (mRS) of 0 or 1 (Appendix 4);

9. Baseline CT scan shows no hemorrhage;

10. NIHSS greater than or equal to 8 (Appendix 3);

11. Patient is capable of complying with study procedures and agrees to complete all required study procedures, study visits and associated activities;

12. Legally authorized representative must be able to understand and give written informed consent. Patient will assent if capable. Patient may be re-consented once it is established that there is no memory loss or cognitive impairment.

1. Age ≥18 and ≤85;

2. Signs and symptoms consistent with an acute ischemic stroke with anterior circulation large vessel occlusion (M1 MCA, carotid-terminus occlusion, Tandem occlusion allowed (Extracranial ICA+carotid T or M1 MCA)) as determined by CT imaging; (i.e., hyper dense sign on non-contrast CT or CT angiogram);

3. Ability to perform arterial puncture within 24 hours from symptom onset or LKN;

4. ASPECT score of 6-10 on non-contrast CT of the brain if under 80 years; ASPECTS 9-10 if age 80-85;

5. For transfer patients with anticipated arterial puncture greater than 6 hours from symptom onset or LKN, qualifying imaging must be performed within 2 hours prior to enrolling hospital arrival or with a newly obtained non-contrast CT scan if this time is exceeded;

6. Candidate for endovascular thrombectomy therapy in accordance with best practices per AHA standard stroke guidelines meeting all labeling requirements for EVT in the trial;

7. No contraindications to general anesthesia, conscious sedation or allergies to any components associated with the anticipated diagnostic or treatment procedures that cannot be treated;

8. A pre-stroke mRS of 0 or 1 (Appendix 4);

9. Baseline CT scan shows no hemorrhage;

10. NIHSS greater than or equal to 8 (Appendix 3);

11. Patient is capable of complying with study procedures and agrees to complete all required study procedures, study visits and associated activities;

12. Legally authorized representative must be able to understand and give written informed consent. Patient will assent if capable. Patient may be re-consented once it is established that there is no memory loss or cognitive impairment.

Exclusion Criteria

1. Patient arrives to the enrolling hospital intubated

2. Female patients of childbearing potential who are known to be or may be pregnant;

3. The patient has a known history of bleeding diathesis, coagulopathy, cryoglobulinemia, sickle cell anemia, will refuse blood transfusions or contraindication to heparin; history of genetically confirmed hypercoagulable syndrome

4. The patient has a height of < 1.5 meters (4 feet 11 inches);

5. Use of warfarin with INR > 1.7;

6. Blood clinical chemistry potassium (K+) < 2.7;

7. History of severe dementia and currently taking medication for cognitive impairment or behavior disorder;

8. End stage renal disease on hemodialysis;

9. Known presence of an IVC filter;

10. Contrast dye allergy with history of anaphylaxis, known serious sensitivity to contrast agents or any condition in which angiography is contraindicated;

11. Known to have contraindications to radiological imaging;

12. Known allergy to meperidine or buspar or dexmedetomidine;

13. Sustained hypertension (SBP > 185 or DBP > 110 unable to be treated with a continuous infusion, e.g., nicardipine);

14. Baseline CT/MR showing evidence of arterial vasculitis or dissection;

15. Baseline CT/MR evidence of multiple vascular territory acute stroke;

16. Excessive tortuosity of cervical vessels;

17. Intracranial stent in area that may impact Recanalization;

18. Presence of Pulmonary embolism, ilio-femoral or deep vein thrombosis

19. Presence of clinical signs of sepsis

20. Ongoing or spontaneous atrial fibrillation indicating severe peripheral vascular disease, aortic disease, or proximal cerebrovascular disease that in the opinion of the investigator precludes access or safe endovascular treatment

21. Presence of any other serious comorbidity that would be likely to impact life expectancy to less than 6 months or limit Patient cooperation or study compliance

22. Concurrent participation in an investigational clinical study (excluding registries) that has not completed the follow-up period or planned participation in another study within the next 3 months;

23. Patient has any other condition(s) or circumstance(s) that, in the judgement of the investigator, might interfere with or impact the collection of high quality data, or with the completion of follow up requirements within the study windows.

24. Patient has active or symptomatic COVID-19

25. Patients without a legally authorized representative to sign the consent form will be excluded.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

ZOLL Circulation, Inc., USA

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Rishi Gupta, MD, MBA

Role: PRINCIPAL_INVESTIGATOR

Wellstar Medical Group

Locations

WellStar Kennestone Regional Medical Center

Marietta, Georgia, United States

The Queen's Medical Center

Honolulu, Hawaii, United States

University of Chicago Medical Center

Chicago, Illinois, United States

University of Maryland Medical Center

Baltimore, Maryland, United States

Henry Ford

Detroit, Michigan, United States

ProMedica Toledo Hospital

Toledo, Ohio, United States

Mercy Health

Toledo, Ohio, United States

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, United States

Countries

United States

Other Identifiers

EDC-3599

Identifier Type: -

Identifier Source: org_study_id